Molecular Partners starts Phase II of MP0250 in MM

Molecular Partners AG (SIX:MOLN) began an open-label, European Phase II trial to evaluate MP0250 in combination with Velcade bortezomib plus dexamethasone in about 40 patients with refractory and relapsed multiple myeloma (MM). Patients will receive 6, 8 or 12 mg/kg IV MP0250 every 3 weeks until progression or toxicity. The company expects data from the trial this year and additional data in 2018.

The trial’s primary endpoint is overall response rate (ORR). Secondary endpoints include safety, immunogenicity, progression-free survival (PFS) and duration of response...